Exemption number e2019001.(b)(4).The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other incidents from this lot.It should be noted that the xience xpedition everolimus eluting coronary stent system instruction for use states: note: do not exceed rbp as indicated on product label.Balloon pressures should be monitored during inflation.Use of pressures higher than specified on product label may result in a ruptured balloon with possible intimal damage and dissection.The investigation determined the reported difficulties appear to be related to circumstances of the procedure as it is likely the device interacted with the 80% stenosed, moderately tortuous and heavily calcified causing the reported difficulty to advance.After the device was advanced to the lesion the balloon was inflated above the labeled rated burst pressure (against instructions for use) causing the reported material rupture.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was performed to treat an 80% stenosed, moderately tortuous, and heavily calcified de novo lesion in the right coronary artery.Resistance with the anatomy was felt when advancing a 2.5x48mm xience xpedition stent delivery system (sds).The balloon ruptured at 20 atmospheres.The sds was removed with the stent still on the balloon.The procedure was successfully completed with the deployment of a 2.75x48mm xience xpedition stent.There were no adverse patient effects and no clinically significant delay in the procedure.No additional information was provided.
|